# DESCRIPTION

## FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

- acknowledge government support

## BACKGROUND

- describe necrotizing enterocolitis

## SUMMARY

- define AHR agonist compounds
- describe compound structures
- outline methods of treatment

## DETAILED DESCRIPTION

- describe patent application structure and content

### A. Compounds

- define AHR agonist compounds of formula (I)
- describe variations of compounds of formula (I)

### B. Methods of Treatment

- describe method for treating inflammatory disorders using AHR agonists
- define subject and treatment
- describe inflammatory disorders
- describe administration methods
- define effective amount and prophylactic treatment
- describe combination therapy

### C. Infant Nutritional Formula Comprising Aryl Hydrocarbon Receptor (AHR) Agonists for the Prevention and Treatment of Inflammatory Disorders

- formulate infant nutritional formula with AHR agonists

### D. Maternal Administration of an Aryl Hydrocarbon Receptor (AHR) Agonist

- administer AHR agonist to pregnant mother

### E. Pharmaceutical Compositions and Administration

- formulate pharmaceutical composition with AHR agonist
- describe pharmaceutically acceptable salts
- outline modes of administration
- detail pharmaceutical preparations for oral use

### F. Definitions

- define terms generically
- specify substituent groups
- explain hydrocarbon and alkyl terms
- detail branched and cyclic alkyl groups
- define heteroalkyl and cycloheteroalkyl groups
- describe cycloalkyl and heterocycloalkyl ring systems
- define alkenyl
- define cycloalkenyl
- define alkynyl
- define alkylene
- define heteroalkylene
- define aryl and heteroaryl
- define chemical terms
- define stereochemical forms
- describe isotopic variations
- describe salt forms
- describe prodrugs
- describe protecting groups
- define general terms
- describe numerical values

## EXAMPLES

- provide guidance

### Example 1

- define abbreviations
- introduce NEC disease
- motivate maternal-fetal signaling
- summarize NEC pathogenesis
- describe AHR signaling
- outline experimental design
- present results of I3C administration
- analyze AHR expression in NEC
- investigate AHR activation mechanisms
- identify AHR ligand A18
- discuss therapeutic potential of A18
- discuss NEC pathogenesis
- motivate AHR signaling in NEC
- describe AHR ligand discovery
- outline NEC induction in mice
- outline NEC induction in piglets
- describe AHR induction in pregnant mice
- detail enteroid harvesting and culture
- outline human ileal sample collection and explant culture
- describe RNA isolation and quantification

### Example 2

- motivate prevention of NEC
- describe AHR agonist identification
- outline general considerations for synthesis
- detail synthesis of pyridine-imidazole series
- provide spectral data for synthesized compounds
- describe synthesis procedures
- report experimental results
- prepare 2-methylenehydroxy-3-methyl-4-ethoxypyridine
- prepare 2-methylenehydroxy-3-methyl-4-phenoxypyridine and 2-methylenehydroxy-3-methyl
- prepare 5-fluoro-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyrid
- prepare 5-methyl-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin
- prepare compounds
- synthesize compounds
- oxidize compounds
- characterize compounds
- prepare compounds 26-31
- describe synthesis of compounds 26-31
- provide characterization data for compounds 26-31
- prepare compound 31 oxoquinazoline series
- prepare 2-oxoquinazoline
- prepare 2-thioquinazoline and 2-chloromethylbenzimidazole
- prepare 4-(((1H-benzo[d]imidazol-2-yl)methyl)thio)quinazoline and derivatives
- synthesize quinazoline derivatives
- characterize synthesized compounds
- report experimental procedures

### Example 3

- overview of AHR activation and NEC treatment
- describe experimental results and methods

